Anthropic has acquired Coefficient Bio, a biotech AI startup founded eight months ago, in a stock deal valued at over $400 million. This acquisition adds a team of fewer than 10 individuals, most of whom are former Genentech computational biology researchers, to Anthropic’s healthcare and life sciences division. The move signifies more than just acquiring talent; it demonstrates the maker of Claude’s commitment to utilizing general-purpose AI for advancing drug discovery.
The deal, first reported by The Information, involves a company without publicly known products, revenue, or conventional metrics. Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, both formerly of Prescient Design, Genentech’s computational drug discovery unit. Frey led innovative research in biological foundation models and machine learning for biomolecule design, and his work includes over 20 publications and an ICLR Outstanding Paper Award in 2024.
Coefficient Bio aimed to create AI for scientific advancement, developing a platform for AI to draft drug research plans, manage clinical strategies, and identify drug candidates. Despite its stealth mode, Dimension, a venture firm focusing on tech and life sciences, owned about half the company, now reporting a 38,513 percent return on its investment. This highlights the rapid revaluation of AI in early-stage science, aligning with Anthropic’s $380 billion valuation post-Series G round in February.
The Coefficient Bio team will integrate into Anthropic’s Health Care Life Sciences group, under Eric Kauderer-Abrams. His goal is for Claude to dominate AI in biology, akin to its role in coding, aiming for significant global life science work to run on Claude. The platform, integrating with Benchling, PubMed, and 10x Genomics, is designed to assist researchers throughout the drug discovery process.
This acquisition strengthens Anthropic’s push with Claude for Life Sciences, bringing domain-specific expertise crucial for developing tools tailored for pharmaceutical companies. Anthropic enters a competitive field with other companies like Google DeepMind’s Isomorphic Labs and Nvidia’s partnership with Eli Lilly advancing AI-designed drug discovery. OpenAI’s collaboration with Moderna for personalized cancer vaccines also highlights the sector’s growth.
The surge in venture capital interest in AI-biology crossovers is evident, with Breakout Ventures raising $114 million for early-stage biotechs and Dimension reportedly planning a $700 million fund. The aim is to harness the AI wave in life sciences as in software engineering.
For Anthropic, the strategy is clear: its annual revenue has reached $14 billion, growing significantly across coding, enterprise search, and productivity, with healthcare and life sciences seen as expansive markets for further integration and revenue growth. The $400 million stock purchase of pre-revenue Coefficient Bio is less a valuation of existing assets and more a strategic investment in potential advancements led by Coefficient’s researchers.
Ultimately, whether this bet yields returns hinges on whether frontier AI models can deliver genuine scientific breakthroughs or remain costly literature review tools familiar with molecular biology.